SCPH - SCファ―マシュ―ティカルズ (scPharmaceuticals Inc.) SCファ―マシュ―ティカルズ

 SCPHのチャート


 SCPHの企業情報

symbol SCPH
会社名 scPharmaceuticals Inc (SCファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 scファーマスーティカルズ(scPharmaceuticals Inc.)は生物医薬品企業である。同社は皮下送達用医薬品の開発に従事する。同社は標準の医療用接着剤を使用して身体に取り付けられる小型ポンプであるsc2Wear Infusorを提供する。sc2Wear Infusorは静脈内点滴と同様に、薬物を体内に注入する。同社の製品はsc2Wear Infusorを介して皮下投与される。同社のパイプラインプログラムには急性期治療以外の心不全患者の利尿用sc2Wear Infusorを介して提供されるフロセミドの皮下製剤を含むscFurosemideリード製品候補であるFuroscixを含む。同社はFuroscixの2つの臨床試験、4つの臨床試験、12のヒト因子試験、およびグラム陽性およびグラム陰性菌による感染の治療用静脈内使用の抗生物質scCeftriaxoneを完了した。   SCファ―マシュ―ティカルズは米国の医薬品企業。主に治療法の開発、患者に対するケアの高度化、医療費の削減につながる可能性のある医薬品の開発・商業化に従事する。同社の製品候補には心不全など心臓疾患に対する治療薬、また感染症などの治療薬を含む。本社所在地はマサチュ―セッツ州バ―リントン。   scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA.
本社所在地 2400 District Avenue Suite 310 Burlington MA 01803 USA
代表者氏名 John H. Tucker ジョンH.タッカー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-517-0730
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.scpharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/scph
adr_tso
EBITDA EBITDA(百万ドル) -30.38400
終値(lastsale) 5.43
時価総額(marketcap) 100831239.27
時価総額 時価総額(百万ドル) 82.07626
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -7.30674
当期純利益 当期純利益(百万ドル) -30.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Scpharmaceuticals Inc revenues was not reported. Net loss increased 62% to $18.6M. Higher net loss reflects General and administrative increase from $4.4M to $9.7M (expense) Research and development increase of 27% to $8.9M (expense) Interest expense increase from $132K to $701K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.65 to -$1.00.

 SCPHのテクニカル分析


 SCPHのニュース

   scPharmaceuticals names Rachael Nokes as CFO  2022/12/19 13:10:13 Seeking Alpha
scPharmaceuticals (SCPH) said Monday it appointed Rachael Nokes, SVP of finance, as CFO.Nokes joined the company in 2014 from BG Medicine, a publicly traded medical device company,…
   MCRB, TASK and LILAK are among after hours mover  2022/12/07 22:56:49 Seeking Alpha
Gainers: scPharmaceuticals (SCPH) +9%. HashiCorp (HCP) +9%
   Analysts Set scPharmaceuticals Inc. Target Price at $16.40  2022/12/04 06:55:12 Business Mag
Shares of scPharmaceuticals Inc. have received a consensus rating of “Buy” from the six analysts that are covering the stock, MarketBeat reports. Five investment analysts have…
   Boom Or Bust: What Are scPharmaceuticals Inc.’s (NASDAQ:SCPH) Future Prospects?  2022/12/03 15:30:00 Marketing Sentinel
scPharmaceuticals Inc. (NASDAQ:SCPH)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 0.19. At the close of trading, the stock’s price was $7.05, to imply a decrease of -0.98% or -$0.07 in intraday trading. The SCPH share’s 52-week high remains $7.96, putting it -12.91% down since that peak … Boom Or Bust: What Are scPharmaceuticals Inc.’s (NASDAQ:SCPH) Future Prospects? Read More »
   How Are Things Looking For scPharmaceuticals Inc. (NASDAQ: SCPH) For The Short Term?  2022/11/23 12:30:00 Stocks Register
scPharmaceuticals Inc. (NASDAQ:SCPH) traded at $6.97 at close of the session on Tuesday, 11/22/22, made an upward move of 14.45% on its previous day’s price. Looking at the stock we see that its previous close was $6.09 and the beta (5Y monthly) reads 0.23 with the day’s price range being $5.80 – $7.33. In terms … How Are Things Looking For scPharmaceuticals Inc. (NASDAQ: SCPH) For The Short Term? Read More »
   scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference  2022/09/01 12:00:00 GlobeNewswire
BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to present virtually at the H.C. Wainwright 24 th Annual Global Investment Conference, which is being held in a hybrid format, in-person and virtually, from September 12-14 in New York.
   scPharmaceuticals GAAP EPS of -$0.35 misses by $0.05  2022/08/09 12:35:52 Seeking Alpha
scPharmaceuticals press release (SCPH): Q2 GAAP EPS of -$0.35 misses by $0.05.“The key highlight of the second quarter of 2022 was clearly the FDA’s acceptance of our FUROSCIX NDA…
   scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update  2022/08/09 11:00:00 GlobeNewswire
Announced FDA acceptance of FUROSCIX ® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022
   scPharmaceuticals Inc. to Host FUROSCIX (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients  2022/06/30 12:00:00 Wallstreet:Online
Virtual event scheduled for Wednesday, July 13 at 10:00 AM EDT BURLINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Company is hosting
   scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference  2022/05/17 12:00:00 GlobeNewswire
BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24 at 3:00pm EDT, at the Fontainebleau Miami Beach Hotel in Miami, FL.
   scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference  2022/09/01 12:00:00 GlobeNewswire
BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to present virtually at the H.C. Wainwright 24 th Annual Global Investment Conference, which is being held in a hybrid format, in-person and virtually, from September 12-14 in New York.
   scPharmaceuticals GAAP EPS of -$0.35 misses by $0.05  2022/08/09 12:35:52 Seeking Alpha
scPharmaceuticals press release (SCPH): Q2 GAAP EPS of -$0.35 misses by $0.05.“The key highlight of the second quarter of 2022 was clearly the FDA’s acceptance of our FUROSCIX NDA…
   scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update  2022/08/09 11:00:00 GlobeNewswire
Announced FDA acceptance of FUROSCIX ® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022
   scPharmaceuticals Inc. to Host FUROSCIX (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients  2022/06/30 12:00:00 Wallstreet:Online
Virtual event scheduled for Wednesday, July 13 at 10:00 AM EDT BURLINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Company is hosting
   scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference  2022/05/17 12:00:00 GlobeNewswire
BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24 at 3:00pm EDT, at the Fontainebleau Miami Beach Hotel in Miami, FL.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 SCファ―マシュ―ティカルズ SCPH scPharmaceuticals Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)